• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿 miR-21-5p 作为预测他达拉非治疗良性前列腺增生疗效的潜在生物标志物。

Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia.

作者信息

Tanaka Tomoaki, Minami Akinori, Tashiro Kouichiro, Yoshida Naomasa, Tohda Akira, Yamakoshi Yasuo, Yasumoto Ryoji, Sugita Shozo, Nakatani Tatsuya

机构信息

Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan.

Department of Urology, Meijibashi Hospital, Matsubara, Osaka, Japan.

出版信息

Future Sci OA. 2018 Mar 15;4(6):FSO304. doi: 10.4155/fsoa-2018-0012. eCollection 2018 Jul.

DOI:10.4155/fsoa-2018-0012
PMID:30057782
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6060390/
Abstract

AIM

To investigate whether urine levels of miRNAs that regulate the function of endothelial cells are associated with effectiveness in benign prostatic hyperplasia (BPH) patients treated with a phosphodiesterase type 5 inhibitor, tadalafil.

PATIENTS & METHODS: We measured urine levels of three miRNAs (miR-21-5p, miR-126-5p & miR-155-5p) in 55 BPH patients before and after tadalafil administration to understand its effectiveness.

RESULTS

Baseline urine miR-21-5p level was an independent predictor of response to tadalafil in multivariate regression analysis (odds ratio: 0.28; 95% CI: 0.10-0.77; p = 0.014). Receiver operator curve analysis revealed that baseline urine miR-21-5p could serve as a predictor of response (area under curve: 0.85; 95% CI: 0.75-0.95; p < 0.001).

CONCLUSION

Urine miR-21-5p could serve as a biomarker in predicting response of tadalafil for BPH.

摘要

目的

研究调节内皮细胞功能的微小RNA(miRNA)尿液水平是否与5型磷酸二酯酶抑制剂他达拉非治疗良性前列腺增生(BPH)患者的疗效相关。

患者与方法

我们在55例BPH患者服用他达拉非前后测量了三种miRNA(miR-21-5p、miR-126-5p和miR-155-5p)的尿液水平,以了解其疗效。

结果

在多变量回归分析中,基线尿液miR-21-5p水平是他达拉非反应的独立预测因子(比值比:0.28;95%置信区间:0.10-0.77;p=0.014)。受试者工作特征曲线分析显示,基线尿液miR-21-5p可作为反应的预测指标(曲线下面积:0.85;95%置信区间:0.75-0.95;p<0.001)。

结论

尿液miR-21-5p可作为预测他达拉非治疗BPH反应的生物标志物。

相似文献

1
Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia.尿 miR-21-5p 作为预测他达拉非治疗良性前列腺增生疗效的潜在生物标志物。
Future Sci OA. 2018 Mar 15;4(6):FSO304. doi: 10.4155/fsoa-2018-0012. eCollection 2018 Jul.
2
Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.每日服用5毫克他达拉非可改善良性前列腺增生患者的内皮功能。
Aging Male. 2018 Mar;21(1):77-82. doi: 10.1080/13685538.2017.1367922. Epub 2017 Aug 22.
3
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.他达拉非对良性前列腺增生继发的下尿路症状及对同时患有这两种病症的性活跃男性勃起功能障碍的影响:来自四项随机、安慰剂对照他达拉非临床研究的汇总数据分析
J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19.
4
Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia.磷酸二酯酶 5 抑制剂他达拉非通过 miR-3126-3p/FGF9 轴减少良性前列腺增生中的前列腺纤维化。
Biol Direct. 2024 Aug 2;19(1):61. doi: 10.1186/s13062-024-00504-y.
5
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.他达拉非每日一次治疗男性下尿路症状(LUTS)合并良性前列腺增生(BPH)而无勃起功能障碍。
BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13.
6
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.使用他达拉非或其他5型磷酸二酯酶抑制剂组合治疗的同时患有良性前列腺增生和勃起功能障碍的男性的治疗满意度。
Patient Prefer Adherence. 2016 Jul 12;10:1205-15. doi: 10.2147/PPA.S105241. eCollection 2016.
7
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.每日一次坦索罗辛 5 毫克治疗伴或不伴勃起功能障碍的下尿路症状提示良性前列腺增生症男性的疗效:自然观察性 TadaLutsEd 研究结果。
J Sex Med. 2014 Feb;11(2):498-505. doi: 10.1111/jsm.12386. Epub 2013 Nov 13.
8
Tadalafil - a therapeutic option in the management of BPH-LUTS.他达拉非——治疗良性前列腺增生相关下尿路症状的一种选择。
Int J Clin Pract. 2014 Jan;68(1):94-103. doi: 10.1111/ijcp.12305.
9
Tadalafil for the treatment of benign prostatic hyperplasia.他达拉非治疗良性前列腺增生。
Expert Opin Pharmacother. 2019 Jun;20(8):929-937. doi: 10.1080/14656566.2019.1589452. Epub 2019 Mar 22.
10
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.磷酸二酯酶-5 抑制剂与良性前列腺增生。
Curr Opin Urol. 2010 Jan;20(1):49-54. doi: 10.1097/MOU.0b013e328333ac68.

引用本文的文献

1
Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia.雄激素受体拮抗剂MDV3100治疗对良性前列腺增生大鼠的影响。
Int Neurourol J. 2021 Sep;25(3):219-228. doi: 10.5213/inj.2142004.002. Epub 2021 Sep 30.

本文引用的文献

1
Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.每日服用5毫克他达拉非可改善良性前列腺增生患者的内皮功能。
Aging Male. 2018 Mar;21(1):77-82. doi: 10.1080/13685538.2017.1367922. Epub 2017 Aug 22.
2
Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.男性下尿路症状和良性前列腺增生临床指南。
Int J Urol. 2017 Oct;24(10):716-729. doi: 10.1111/iju.13401. Epub 2017 Jul 26.
3
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
下尿路症状/良性前列腺增生与血管功能:一氧化氮-5型磷酸二酯酶-环磷酸鸟苷途径的作用
Int J Urol. 2017 Jun;24(6):412-424. doi: 10.1111/iju.13336. Epub 2017 Mar 22.
4
Tadalafil for male lower urinary tract symptoms improves endothelial function.他达拉非用于男性下尿路症状可改善内皮功能。
Int J Urol. 2017 Mar;24(3):206-210. doi: 10.1111/iju.13273. Epub 2016 Dec 29.
5
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.基线时报告的心血管危险因素、相关合并症及药物治疗对伴有良性前列腺增生的下尿路症状男性每日一次服用5毫克他达拉非治疗反应的影响:四项随机、双盲、安慰剂对照临床试验的综合分析
Int J Clin Pract. 2015 Dec;69(12):1496-507. doi: 10.1111/ijcp.12722. Epub 2015 Aug 24.
6
Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.磷酸二酯酶5抑制剂他达拉非对部分膀胱出口梗阻大鼠模型膀胱功能的影响。
Neurourol Urodyn. 2016 Apr;35(4):444-9. doi: 10.1002/nau.22732. Epub 2015 Feb 19.
7
Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.他达拉非单次治疗对膀胱过度扩张/排空和腹主动脉夹闭/释放大鼠模型下尿路组织血流的影响。
Eur J Pharmacol. 2015 May 5;754:92-7. doi: 10.1016/j.ejphar.2015.01.050. Epub 2015 Feb 17.
8
EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.EAU 指南:非神经原性男性下尿路症状包括良性前列腺增生的评估。
Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19.
9
Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms.良性前列腺增生患者的代谢综合征与下尿路症状:与储尿期症状的可能联系
Urology. 2014 Nov;84(5):1181-7. doi: 10.1016/j.urology.2014.07.018. Epub 2014 Oct 24.
10
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.微血管功能障碍与 PDE5 抑制剂在 BPH-LUTS 中的疗效。
Nat Rev Urol. 2014 Apr;11(4):231-41. doi: 10.1038/nrurol.2014.53. Epub 2014 Mar 11.